WS Investor
25 Aug 2026, 16:59
Merck Stock Rises 2.7% as Argus and Wolfe Research Raise Price Targets
Merck & Co. (NYSE: MRK) shares rose about 2.7% on Tuesday as two Wall Street firms raised their price targets on the pharmaceutical company while maintaining bullish ratings.
Argus analyst Jasper Hellweg raised the firm's price target on Merck to $170 from $145 while maintaining a Buy rating. Wolfe Research analyst Alexandria Hammond was even more bullish, increasing the firm's target to $180 from $155 and maintaining an Outperform rating.
With Merck trading around $154.73, the new targets imply upside of approximately 10% and 16%, respectively.
## Why the Rating Reports Are Positive for Merck
The simultaneous target increases from two firms signal improving expectations for Merck's earnings and valuation.
Merck remains one of the world's largest pharmaceutical companies, with a strong oncology franchise led by Keytruda and a broader pipeline designed to diversify growth over the longer term. The company's position in oncology and continued investment in new medicines remain central to its growth outlook.
Tuesday's 2.7% gain appears to reflect the positive analyst sentiment, with both firms seeing additional upside even after the stock's recent performance.
Merck & Co. (NYSE: MRK) shares rose about 2.7% on Tuesday as two Wall Street firms raised their price targets on the pharmaceutical company while maintaining bullish ratings.
Argus analyst Jasper Hellweg raised the firm's price target on Merck to $170 from $145 while maintaining a Buy rating. Wolfe Research analyst Alexandria Hammond was even more bullish, increasing the firm's target to $180 from $155 and maintaining an Outperform rating.
With Merck trading around $154.73, the new targets imply upside of approximately 10% and 16%, respectively.
## Why the Rating Reports Are Positive for Merck
The simultaneous target increases from two firms signal improving expectations for Merck's earnings and valuation.
Merck remains one of the world's largest pharmaceutical companies, with a strong oncology franchise led by Keytruda and a broader pipeline designed to diversify growth over the longer term. The company's position in oncology and continued investment in new medicines remain central to its growth outlook.
Tuesday's 2.7% gain appears to reflect the positive analyst sentiment, with both firms seeing additional upside even after the stock's recent performance.
